Anti-beta 1 integrin humanized antibody, and pharmaceutical composition for treating cancer, comprising same
AssigneeSG Medical, Inc.
InventorsJi Chul Lee, Jongchan Park, Sung-Won Min, Hyeong Sun Kwon
Life of this patent
Estimating the term…
Abstract
The present invention relates to a monoclonal antibody or fragment thereof that recognizes and binds specifically to beta 1 integrin as an antigen. The present invention also relates to a pharmaceutical composition for preventing or treating cancer including the monoclonal antibody or fragment thereof. The monoclonal antibody of the present invention is useful in preventing or treating cancer due to its ability to inhibit the proliferation and angiogenesis of cancer cells and effectively induce apoptosis.
Claims14
A monoclonal antibody or fragment thereof that recognizes and binds specifically to beta 1 integrin as an antigen wherein the monoclonal antibody or fragment thereof comprises replaced amino acids at the following positions according to the Kabat EU numbering system:
- a) the heavy chain variable region (VH) SEQ ID NO:
- 1 with substitutions A9S, 120V, T25S, S30T, K67R, S76T, N77D, and Q82E;
- and
- b) the light chain variable region (VL) SEQ ID NO:
- 2 with substitutions V11L, F41Y, and R44K.
Dependencies are inferred from the claim text.